{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:44:51Z","timestamp":1756464291756,"version":"3.44.0"},"reference-count":31,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:p>Navigating the new drug-driving law \u25cf EMA recommends suspension of medicines over trial concerns \u25cf NICE updates approach to biosimilars \u25cf Chondroitin for OA? \u25cf The impact of molluscum contagiosum \u25cf Reassessing treatments for neuropathic pain \u25cf First-line drugs for hypertension \u25cf Stopping smoking and mental health \u25cf Warnings and advice on \u25bc valproate treatment<\/jats:p>","DOI":"10.1136\/dtb.2015.4.0318","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T00:47:09Z","timestamp":1427590029000},"page":"38-41","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["DTB Select: 4 | April 2015"],"prefix":"10.1136","volume":"53","member":"239","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"2025082623060619000_53.4.38.1","unstructured":"Department for Transport, 2014. Guidance for healthcare professionals on drug driving [online]. Available: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/325275\/healthcare-profs-drug-driving.pdf [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.2","unstructured":"Department for Transport, 2014. Drug driving information and announcements [online]. Available: https:\/\/www.gov.uk\/government\/collections\/drug-driving [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.3","unstructured":"Royal Pharmaceutical Society, 2015. New support resource for changes to drug driving rules [online]. Available: http:\/\/www.rpharms.com\/what-s-happening-\/news_show.asp?id=2455&num; [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.4","unstructured":"European Medicines Agency, 2015. GVK Biosciences: European Medicines Agency recommends suspending medicines over flawed studies [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/01\/news_detail_002256.jsp&mid=WC0b01ac058004d5c1 [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.5","unstructured":"European Medicines Agency, 2015. Products for which the marketing authorisations are recommended for suspension by the CHMP on 22 January 2015 [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2015\/01\/WC500180894.pdf [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.6","unstructured":"Medicines and Healthcare products Regulatory Agency, 2015. GVK Biosciences: MHRA responds to European Medicines Agency's recommendation to suspend medicines [online] Available: https:\/\/www.gov.uk\/government\/news\/gvk-biosciences-mhra-responds-to-european-medicines-agencys-recommendation-to-suspend-medicines [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.7","unstructured":"European Medicines Agency, 2015. GVK Biosciences [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/GVK_Biosciences\/human_referral_000382.jsp&mid=WC0b01ac05805c516f [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.8","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2015.3.0316"},{"key":"2025082623060619000_53.4.38.9","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2013.5.0181"},{"key":"2025082623060619000_53.4.38.10","unstructured":"National Institute for Health and Care Excellence, 2015. NICE's biosimilars position statement [online]. Available: http:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/biosimilars-statement.pdf [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.11","unstructured":"National Institute for Health and Care Excellence, 2015. Evaluating biosimilar medicines [online]. Available: http:\/\/www.nice.org.uk\/news\/article\/evaluating-biosimilar-medicines [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.12","unstructured":"European Medicines Agency, 2013. Inflectra [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002778\/human_med_001677.jsp&mid=WC0b01ac058001d124 [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.13","unstructured":"European Medicines Agency, 2013. Remsima [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002576\/human_med_001682.jsp&mid=WC0b01ac058001d124 [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.14","doi-asserted-by":"crossref","unstructured":"Wandel S , et al . Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: c4675.","DOI":"10.1136\/bmj.c4675"},{"key":"2025082623060619000_53.4.38.15","unstructured":"National Institute for Health and Care Excellence, 2014. Osteoarthritis: care and management in adults (CG 177) [online]. Available: https:\/\/www.nice.org.uk\/guidance\/cg177 [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.16","doi-asserted-by":"crossref","unstructured":"Singh JA , et al . Chondroitin for osteoarthritis. Cochrane Database Syst Rev 2015; 1: CD005614. DOI:10.1002\/14651858.CD005614.pub2 [Last assessed as up-to-date 14 November 2013].","DOI":"10.1002\/14651858.CD005614.pub2"},{"key":"2025082623060619000_53.4.38.17","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2014.10.0285"},{"key":"2025082623060619000_53.4.38.18","unstructured":"National Institute for Health and Care Excellence, 2012. Clinical Knowledge Summaries: Molluscum contagiosum [online] Available: http:\/\/cks.nice.org.uk\/molluscum-contagiosum [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1473-3099(14)71053-9","article-title":"Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study","volume":"15","author":"Olsen","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2025082623060619000_53.4.38.20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacothearpy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"2025082623060619000_53.4.38.21","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2012.10.0133"},{"key":"2025082623060619000_53.4.38.22","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2012.11.0139"},{"key":"2025082623060619000_53.4.38.23","unstructured":"National Institute for Health and Care Excellence, 2011. Hypertension: clinical management of primary hypertension in adults (CG 127) [online]. Available: https:\/\/www.nice.org.uk\/guidance\/cg127 [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.24","doi-asserted-by":"crossref","unstructured":"Xue H , et al . First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2015; 1: CD008170. DOI:10.1002\/14651858.CD008170.pub2 [Last assessed as up-to-date 10 December 2014].","DOI":"10.1002\/14651858.CD008170.pub2"},{"key":"2025082623060619000_53.4.38.25","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2011.02.0070"},{"key":"2025082623060619000_53.4.38.26","unstructured":"US Department of Health and Human Services, 2014. The health consequences of smoking\u201450 years of progress [online]. Available: http:\/\/www.surgeongeneral.gov\/library\/reports\/50-years-of-progress\/exec-summary.pdf [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.27","doi-asserted-by":"crossref","unstructured":"Taylor G , et al . Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ 2014; 348: g1151.","DOI":"10.1136\/bmj.g1151"},{"issue":"(6)","key":"2025082623060619000_53.4.38.28","first-page":"1","article-title":"Medicines related to valproate: risk of abnormal pregnancy outcomes","volume":"8","author":"Medicines and Healthcare products Regulatory Agency","year":"2015","journal-title":"Drug Safety Update"},{"key":"2025082623060619000_53.4.38.29","unstructured":"European Medicines Agency, 2014. CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/11\/news_detail_002220.jsp&mid=WC0b01ac058004d5c1 [Accessed 10 March 2015]."},{"key":"2025082623060619000_53.4.38.30","unstructured":"Medicines and Healthcare products Regulatory Agency, 2015. Guide for healthcare professionals. What you should know about the risks of valproic acid use in female patients [online]. Available: https:\/\/www.cas.dh.gov.uk\/ViewandAcknowledgment\/ViewAttachment.aspx?Attachment_id=102095 [Accessed 18 March 2015]."},{"key":"2025082623060619000_53.4.38.31","unstructured":"Medicines and Healthcare products Regulatory Agency, 2015. Patient booklet\u2014valproate [online]. Available: https:\/\/www.cas.dh.gov.uk\/ViewandAcknowledgment\/ViewAttachment.aspx?Attachment_id=102092 [Accessed 18 March 2015]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2015.4.0318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:06:16Z","timestamp":1756274776000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2015.4.0318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,8]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1136\/dtb.2015.4.0318"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2015.4.0318","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}